TVTX Q1 2018 Earnings — Travere Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

TVTXTravere Therapeutics, Inc.

$3B

Q1 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$38M+14.3% YoY

Gross Profit

$37M95.8% margin

Operating Income

-$18M-46.6% margin

Net Income

-$18M-47.8% margin

EPS (Diluted)

$-0.46

QoQ Revenue Growth

-8.9%

Cash Flow

Operating Cash Flow

-$15M

Free Cash Flow

-$23M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$501M

Total Liabilities

$201M

Stockholders' Equity

$299M

Cash & Equivalents

$61M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$38M	$34M	+14.3%
Gross Profit	$37M	$33M	+11.9%
Operating Income	-$18M	-$14M	-24.3%
Net Income	-$18M	-$11M	-65.7%

Revenue Segments

Thiola License

$20M52%

Bile Acid Products

$19M48%